Recent Updates
Recently added Catalysts
CGON Positive Sentiment

ONCLIVE

Wednesday, January 3, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The FDA has granted Fast Track and Breakthrough Therapy designations to Cretostimogene Grenadenorepvec for the treatment of non-muscle invasive bladder cancer (NMIBC). These designations are expected to expedite the development and review process, enhancing treatment options for patients with high-risk conditions. This marks a significant advancement for CG Oncology in their therapeutic offerings.

Market Sentiment Analysis

POSITIVE FACTORS

  • Cretostimogene Grenadenorepvec received Fast Track designation.
  • Breakthrough Therapy designation granted for NMIBC treatment.
  • Positive implications for patients with high-risk conditions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Jan 3, 2024 | in-the-news | 0 comments
FDA Grants Fast Track, Breakthrough Therapy Designations to Cretostimogene Grenadenorepvec for NMIBC

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What designations did the FDA grant to Cretostimogene Grenadenorepvec?

The FDA granted Fast Track and Breakthrough Therapy designations.

What condition is Cretostimogene Grenadenorepvec targeting?

It targets non-muscle invasive bladder cancer (NMIBC).

What is the significance of these FDA designations?

They expedite the development and review process for new therapies.

Who is the developer of Cretostimogene Grenadenorepvec?

CG Oncology is the developer of this therapy.

ShareAdd on Google
Tags: CGON Viatris Investor Conferences Healthcare Cretostimogene Grenadenorepvec NMIBC FDA Fast Track Breakthrough Therapy CG Oncology
Last updated: Jan 3, 2024

Biotech snapshot

Cash runway
$1028M liquidity · $15M/mo burn
~66 mo
Minimal dilution risk
Lead asset
CG0070Phase 2
Non Muscle Invasive Bladder Cancer →

Catalyst track record

+139%
best trade around CGON's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for CGON.

See every catalyst's timing & PoA →